Hana Biosciences to present Marqibo data for acute lymphoblastic leukemia at ASH Annual Meeting

Nov 30 2010NewsGuard 100/100 Score

Hana Biosciences (OTCBB:HNAB), a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that data regarding Marqibo for treatment of adults with relapsed/refractory acute lymphoblastic leukemia (ALL) will be the subject of two presentations at the 2010 Annual Meeting and Exposition of the American Society of Hematology (ASH) being held in Orlando, Florida from December 4-7, 2010.

Presentation details are as follows:

Abstract: 2142: Marqibo® (vincristine sulfate liposomes injection; VSLI) Optimizes the Dosing, Delivery, and Pharmacokinetic (PK) Profile of Vincristine Sulfate (VCR) In Adults with Relapsed and Refractory Acute Lymphoblastic Leukemia (ALL)

Abstract: 2143: Marqibo® (vincristine sulfate liposomes injection; VSLI) In the Treatment of Adult Patients with Advanced, Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL): A Combined Analysis of the VSLI-06 and RALLY Studies

The abstracts are available online at:

http://ash.confex.com/ash/2010/webprogram/Paper33455.html
http://ash.confex.com/ash/2010/webprogram/Paper34609.html

Source: Hana Biosciences, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , , , ,

Comments (0)

Suggested Reading

Leukemia cells depend on P-bodies for growth and survival
New genomic predictors of relapse in childhood B-cell acute lymphoblastic leukemia uncovered
Future directions and challenges in harnessing NK cells against Acute Myeloid Leukemia
Innovative triplet therapy shows encouraging results in advanced chronic myeloid leukemia
Case Western Reserve University receives grant to investigate AML treatment for veterans
Study uncovers genetic changes linked to leukemia risk in people with Down's syndrome
$1.2 million NIH grant may help unravel the interplay between Down syndrome and myeloid leukemia
Study reveals a paradigm shift in the understanding of T-lineage acute lymphoblastic leukemia

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
UC's Eric Vick receives major grants to advance research into combination therapy for leukemia